Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dichloride with Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
NCT02928029Phase 2Terminated
- Sponsor
- Bayer
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Radiopharmaceutical
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of radium-223 dichloride in multiple myeloma (MM) (4 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 9 weeks and Treatment-Emergent Adverse Events at 2 years. Started Feb 2017; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02928029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928029.